Open AccessAntitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models
Author(s) -
Maria Virginia Giolito,
Cristián M. Camacho,
Maitena MartinezAmezaga,
Carla I. Traficante,
Rocío Giordano,
Patricia G. Cornier,
Ernesto G. Mata,
Carina M. L. Delpiccolo,
Dora B. Boggián,
Antonela Del Giúdice,
Leandro E. Mainetti,
O. Graciela Scharovsky,
Viviana R. Rozados,
María J. Rico
Publication year - 2020
Publication title -
future science oa
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.825
H-Index - 23
ISSN - 2056-5623
DOI - 10.2144/fsoa-2019-0057
Subject(s) - clonogenic assay , apoptosis , in vitro , cancer research , chemistry , adenocarcinoma , mammary tumor , toxicity , mechanism of action , pharmacology , biology , cancer , medicine , biochemistry , breast cancer , organic chemistry
Aim: According to the need for the development of new anticancer agents, we have synthetized novel bioactive compounds and aimed to determine their antitumor action. Materials & methods: We describe in vitro studies evaluating the effect of 35 novel chemical compounds on two triple negative murine mammary adenocarcinoma tumors. Results & conclusion: Three compounds were selected because of their high antitumor activity and their low toxicity to normal cells. Their effect on tumor cells apoptosis, clonogenicity and migratory capacity, were determined. We found that the selected compounds showed inhibition of viability and clonogenic capacity, and promotion of apoptosis. They also decreased the migratory capacity of tumor cells. The results obtained suggest the likelihood of their future use as antitumor and/or antimetastatic agents.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom